• OPEN AN ACCOUNT
Indian Indices
Nifty
24,625.05 198.20
(0.81%)
Sensex
80,364.49 554.84
( 0.70%)
Bank Nifty
54,002.45 346.80
( 0.65%)
Nifty IT
35,740.65 559.40
( 1.59%)
Global Indices
Nasdaq
45,565.88 -92.03
(-0.20%)
Dow Jones
6,481.26 -41.60
(-0.64%)
Hang Seng
42,138.74 -579.73
(-1.36%)
Nikkei 225
9,196.34 9.00
(0.10%)
Forex
USD-INR
87.60 0.00
(0.00%)
EUR-INR
102.16 0.00
(0.00%)
GBP-INR
118.33 0.00
(0.00%)
JPY-INR
0.60 0.00
(0.00%)

EQUITY - MARKET SCREENER

Industry :  
BSE Code
ISIN Demat
Book Value()
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
EPS(TTM)
Face Value()
Div & Yield %
 

Sun Pharma drops as foreign broker downgrades on valuation, execution risks
Aug 26,2025
The broker cited stretched valuations and slower-than-expected traction in speciality drugs. It flagged concerns around psoriasis drug Ilumya's heavy Medicare exposure, potential pricing pressures, and limited earnings visibility despite strong initial uptake. It warned that a 10% price cut in Ilumya could erode Sun Pharma’s EPS by 4%.

Sun Pharmaceutical Industries is the largest pharmaceutical company in India and is a leading generic company in the US as well as Global Emerging Markets.

The company’s consolidated net profit tumbled 19.64% to Rs 2,278.63 crore despite of 10.07% increase in revenue from operations to Rs 13,786.07 crore in Q1 FY26 over Q1 FY25. The drop in profit was primarily due to a one-time exceptional charge of Rs 818 crore during the quarter.